Future Opportunities in Thoracic Surgery: The Cutting Edge
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "General Surgery".
Deadline for manuscript submissions: 25 August 2024 | Viewed by 77
Special Issue Editor
Interests: thoracic surgery; thoracic oncology; lung cancer; sleeve resections; savage surgery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Nowadays, lung cancer is still the leading cause of cancer-related deaths worldwide, and non-small cell lung cancer (NSCLC) accounts for nearly 85%. Surgery is considered the treatment of choice for early-stage lung cancer, whereas locally advanced cancers are considered for multi-modal treatments, including neoadjuvant and adjuvant therapy, beside surgery.
Mortality reduction for NSCLC over the past decade is partly attributed to enhanced treatments and
many ongoing clinical trials have reported encouraging outcomes based on new surgical and oncological aspects. In fact, limited resections as segmentectomies are considered the new standard for surgical treatment for early stage lung cancer up to 2 centimeters of diameters and immunotherapy has been introduced in the neoadjuvant multimodal treatment for advanced stage lung cancer.
In this fascinating era of important innovations, it would be interesting to debate about the novel surgical and oncological strategies. Dealing with surgery, it would be interesting to understand the indications for parenchymal sparing techniques compared to standard surgery, to achieve the same oncological results. Considering the wide spread of target- and immunotherapies, even the indication for surgery not also for curative intentions but even for diagnostic necessities in advanced stage lung cancer is under debate, in order to collect a wide portion of tissue for molecular profile.
Immunotherapy has improved curative effects, prognosis, and tolerability compared with traditional chemotherapy. It would be interesting analyzing the effect of novel pre- and post-surgical therapies and the impact of novel therapies on tissue during surgery.
Dr. Giulio Maurizi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- surgical resection
- immunotherapy
- target therapy
- thoracic surgery
- thoracic oncology
- lung cancer
